{"pmid":32359210,"title":"Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report.","text":["Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report.","The novel coronavirus disease 2019 (COVID-19) is a highly infectious and rapidly spreading disease. There are limited published data on the epidemiology and outcomes of COVID-19 infection among organ transplant recipients. After initial flulike symptoms, progression to an inflammatory phase may occur, characterized by cytokine release rapidly leading to respiratory and multiorgan failure. We report the clinical course and management of a liver transplant recipient on hemodialysis, who presented with COVID-19 pneumonia, and despite completing a 5-day course of hydroxychloroquine, later developed marked inflammatory manifestations with rapid improvement after administration of off-label, single-dose tocilizumab. We also highlight the role of lung ultrasonography in early diagnosis of the inflammatory phase of COVID-19. Future investigation of the effects of immunomodulators among transplant recipients with COVID-19 infection will be important.","Am J Transplant","Hammami, Muhammad Baraa","Garibaldi, Brian","Shah, Pali","Liu, Gigi","Jain, Tania","Chen, Po-Hung","Kim, Amy K","Avdic, Edina","Petty, Brent","Strout, Sara","Fine, Derek M","Niranjan-Azadi, Ashwini","Garneau, William M","Cameron, Andrew M","Monroy Trujillo, Jose M","Gurakar, Ahmet","Avery, Robin","32359210"],"abstract":["The novel coronavirus disease 2019 (COVID-19) is a highly infectious and rapidly spreading disease. There are limited published data on the epidemiology and outcomes of COVID-19 infection among organ transplant recipients. After initial flulike symptoms, progression to an inflammatory phase may occur, characterized by cytokine release rapidly leading to respiratory and multiorgan failure. We report the clinical course and management of a liver transplant recipient on hemodialysis, who presented with COVID-19 pneumonia, and despite completing a 5-day course of hydroxychloroquine, later developed marked inflammatory manifestations with rapid improvement after administration of off-label, single-dose tocilizumab. We also highlight the role of lung ultrasonography in early diagnosis of the inflammatory phase of COVID-19. Future investigation of the effects of immunomodulators among transplant recipients with COVID-19 infection will be important."],"journal":"Am J Transplant","authors":["Hammami, Muhammad Baraa","Garibaldi, Brian","Shah, Pali","Liu, Gigi","Jain, Tania","Chen, Po-Hung","Kim, Amy K","Avdic, Edina","Petty, Brent","Strout, Sara","Fine, Derek M","Niranjan-Azadi, Ashwini","Garneau, William M","Cameron, Andrew M","Monroy Trujillo, Jose M","Gurakar, Ahmet","Avery, Robin"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32359210","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/ajt.15985","locations":["multiorgan"],"e_drugs":["Hydroxychloroquine","tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138495311151104,"score":9.490897,"similar":[{"pmid":32324331,"title":"Covid-19 pneumonia in a kidney transplant recipient successfully treated with Tocilizumab and Hydroxychloroquine.","text":["Covid-19 pneumonia in a kidney transplant recipient successfully treated with Tocilizumab and Hydroxychloroquine.","Coronavirus disease 2019 (Covid-19) pneumonia has been poorly reported in solid-organ transplanted patients; prognosis is uncertain and best management unclear. We describe the case of a 61-year-old kidney transplant recipient with several co-morbidities who was hospitalized and later received a diagnosis of Covid-19 pneumonia; the infection was successfully managed with the use of hydroxychloroquine and a single administration of Tocilizumab, after immunosuppression reduction; the patient did not require mechanical ventilation. During the rapid spread of SARS-CoV-2 pandemic, transplant clinicians should be readily informed about new cases of Covid-19 pneumonia in solid-organ transplant recipients, with focus on therapeutic strategies employed and their outcome.","Am J Transplant","Fontana, Francesco","Alfano, Gaetano","Mori, Giacomo","Amurri, Alessio","Lorenzo, Tei","Ballestri, Marco","Leonelli, Marco","Facchini, Francesca","Damiano, Francesca","Magistroni, Riccardo","Cappelli, Gianni","32324331"],"abstract":["Coronavirus disease 2019 (Covid-19) pneumonia has been poorly reported in solid-organ transplanted patients; prognosis is uncertain and best management unclear. We describe the case of a 61-year-old kidney transplant recipient with several co-morbidities who was hospitalized and later received a diagnosis of Covid-19 pneumonia; the infection was successfully managed with the use of hydroxychloroquine and a single administration of Tocilizumab, after immunosuppression reduction; the patient did not require mechanical ventilation. During the rapid spread of SARS-CoV-2 pandemic, transplant clinicians should be readily informed about new cases of Covid-19 pneumonia in solid-organ transplant recipients, with focus on therapeutic strategies employed and their outcome."],"journal":"Am J Transplant","authors":["Fontana, Francesco","Alfano, Gaetano","Mori, Giacomo","Amurri, Alessio","Lorenzo, Tei","Ballestri, Marco","Leonelli, Marco","Facchini, Francesca","Damiano, Francesca","Magistroni, Riccardo","Cappelli, Gianni"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324331","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ajt.15935","locations":["Hydroxychloroquine"],"e_drugs":["Hydroxychloroquine","tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138493781278724,"score":269.93155},{"pmid":32500942,"title":"Outcome of COVID-19 in Liver Transplant Recipients: a Preliminary Report from Northwestern Italy.","text":["Outcome of COVID-19 in Liver Transplant Recipients: a Preliminary Report from Northwestern Italy.","Covid-19 pandemic is deeply affecting transplant activity worldwide. It is unclear whether solid organ transplant recipients are at increased risk of developing severe complications and how they should be managed, also concerning immunosuppression. This is a report about the course and management of SARS-CoV-2 infection in liver transplant recipients from a single center in Northwestern Italy in the period March-April 2020. Three patients who were treated at our Institution are reported in details, whereas summary data are provided for those managed at peripheral Hospitals. Presentation varied from asymptomatic to rapidly progressive respiratory failure due to bilateral interstitial pneumonia. Accordingly, treatment and changes to immunosuppression were adapted to the severity of the disease. Overall mortality was 20%, whereas Covid-related mortality was 10%. Two cases of prolonged (> 2 months) viral carriage were observed in two asymptomatic patients who contracted the infection in the early course after transplant. Besides depicting Covid-19 course and possible treatment scenarios in liver transplant patients, these cases are discussed in relation to the changes in our practice prompted by Covid-19 epidemic, with potential implications for other transplant programs.","Transpl Infect Dis","Patrono, Damiano","Lupo, Francesco","Canta, Francesca","Mazza, Elena","Mirabella, Stefano","Corcione, Silvia","Tandoi, Francesco","De Rosa, Francesco Giuseppe","Romagnoli, Renato","32500942"],"abstract":["Covid-19 pandemic is deeply affecting transplant activity worldwide. It is unclear whether solid organ transplant recipients are at increased risk of developing severe complications and how they should be managed, also concerning immunosuppression. This is a report about the course and management of SARS-CoV-2 infection in liver transplant recipients from a single center in Northwestern Italy in the period March-April 2020. Three patients who were treated at our Institution are reported in details, whereas summary data are provided for those managed at peripheral Hospitals. Presentation varied from asymptomatic to rapidly progressive respiratory failure due to bilateral interstitial pneumonia. Accordingly, treatment and changes to immunosuppression were adapted to the severity of the disease. Overall mortality was 20%, whereas Covid-related mortality was 10%. Two cases of prolonged (> 2 months) viral carriage were observed in two asymptomatic patients who contracted the infection in the early course after transplant. Besides depicting Covid-19 course and possible treatment scenarios in liver transplant patients, these cases are discussed in relation to the changes in our practice prompted by Covid-19 epidemic, with potential implications for other transplant programs."],"journal":"Transpl Infect Dis","authors":["Patrono, Damiano","Lupo, Francesco","Canta, Francesca","Mazza, Elena","Mirabella, Stefano","Corcione, Silvia","Tandoi, Francesco","De Rosa, Francesco Giuseppe","Romagnoli, Renato"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500942","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/tid.13353","keywords":["covid-19","early infection","immunosuppression","viral carriage"],"topics":["Case Report"],"weight":1,"_version_":1668890966355869697,"score":262.35947},{"pmid":32378314,"title":"Early Experience of COVID-19 in Two Heart Transplant Recipients: Case Reports and Review of Treatment Options.","text":["Early Experience of COVID-19 in Two Heart Transplant Recipients: Case Reports and Review of Treatment Options.","The Coronavirus Disease 2019 (COVID-19) pandemic imposes special challenges to immunocompromised transplant patients. Given the paucity of proven data in treating COVID-19, management of these patients is difficult, rapidly evolving, and is mainly based on anecdotal experience. We report 2 cases of heart transplant (HT) recipients with COVID-19. The first is a 59-year-old female with HT in 2012 who presented on March 20, 2020 with fever, hypoxia and ground-glass opacities on chest x-ray. She quickly progressed to acute hypoxic respiratory failure and vasoplegic shock. Despite reduction in immunosuppression, and treatment with tocilizumab, intravenous immunoglobulin, hydroxychloroquine, lopinavir/ritonavir and broad-spectrum antibiotics, she ultimately passed away from multiorgan failure. The second case is a 75-year-old man with HT in 2000 who presented on April 2, 2020 after curbside testing revealed positive COVID-19. Given a milder presentation compared to the first patient, antimetabolite was discontinued and only hydroxychloroquine was started. Due to lack of clinical improvement several days later, tocilizumab, methylprednisolone, and therapeutic anticoagulation were initiated. The patient clinically improved with decreasing oxygen requirements and was discharged home. These two cases highlight the wide range of different presentations of COVID-19 in HT recipients, and the rapidity with which the management of these patients is evolving.","Am J Transplant","Holzhauser, Luise","Lourenco, Laura","Sarswat, Nitasha","Kim, Gene","Chung, Bow","Nguyen, Ann B","32378314"],"abstract":["The Coronavirus Disease 2019 (COVID-19) pandemic imposes special challenges to immunocompromised transplant patients. Given the paucity of proven data in treating COVID-19, management of these patients is difficult, rapidly evolving, and is mainly based on anecdotal experience. We report 2 cases of heart transplant (HT) recipients with COVID-19. The first is a 59-year-old female with HT in 2012 who presented on March 20, 2020 with fever, hypoxia and ground-glass opacities on chest x-ray. She quickly progressed to acute hypoxic respiratory failure and vasoplegic shock. Despite reduction in immunosuppression, and treatment with tocilizumab, intravenous immunoglobulin, hydroxychloroquine, lopinavir/ritonavir and broad-spectrum antibiotics, she ultimately passed away from multiorgan failure. The second case is a 75-year-old man with HT in 2000 who presented on April 2, 2020 after curbside testing revealed positive COVID-19. Given a milder presentation compared to the first patient, antimetabolite was discontinued and only hydroxychloroquine was started. Due to lack of clinical improvement several days later, tocilizumab, methylprednisolone, and therapeutic anticoagulation were initiated. The patient clinically improved with decreasing oxygen requirements and was discharged home. These two cases highlight the wide range of different presentations of COVID-19 in HT recipients, and the rapidity with which the management of these patients is evolving."],"journal":"Am J Transplant","authors":["Holzhauser, Luise","Lourenco, Laura","Sarswat, Nitasha","Kim, Gene","Chung, Bow","Nguyen, Ann B"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378314","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/ajt.15982","locations":["hypoxia","immunoglobulin","multiorgan"],"e_drugs":["Hydroxychloroquine","tocilizumab","Methylprednisolone","lopinavir-ritonavir drug combination"],"topics":["Case Report"],"weight":1,"_version_":1666262687558926336,"score":260.9373},{"pmid":32330356,"title":"Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States.","text":["Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States.","With the rapidly expanding pandemic of SARS-CoV-2, there is concern that solid organ transplant recipients will be particularly vulnerable to infection and may experience a more severe clinical course. We report four cases of COVID-19 in solid organ transplant recipients including recipients of kidney, liver, lung, and heart transplants. We describe each patient's medical history including transplantation history, their clinical presentation and workup, and their course from diagnosis to either hospital discharge or to improvement in symptoms. These reports demonstrate a range of symptoms, clinical severity, and disease course in solid organ transplant recipients with COVID-19, including two hospitalized patients and two patients managed entirely in the outpatient setting.","Am J Transplant","Kates, Olivia S","Fisher, Cynthia E","Stankiewicz-Karita, Helen C","Shepherd, Amanda K","Church, E Chandler","Kapnadak, Siddhartha G","Lease, Erika D","Riedo, Francis X","Rakita, Robert M","Limaye, Ajit P","32330356"],"abstract":["With the rapidly expanding pandemic of SARS-CoV-2, there is concern that solid organ transplant recipients will be particularly vulnerable to infection and may experience a more severe clinical course. We report four cases of COVID-19 in solid organ transplant recipients including recipients of kidney, liver, lung, and heart transplants. We describe each patient's medical history including transplantation history, their clinical presentation and workup, and their course from diagnosis to either hospital discharge or to improvement in symptoms. These reports demonstrate a range of symptoms, clinical severity, and disease course in solid organ transplant recipients with COVID-19, including two hospitalized patients and two patients managed entirely in the outpatient setting."],"journal":"Am J Transplant","authors":["Kates, Olivia S","Fisher, Cynthia E","Stankiewicz-Karita, Helen C","Shepherd, Amanda K","Church, E Chandler","Kapnadak, Siddhartha G","Lease, Erika D","Riedo, Francis X","Rakita, Robert M","Limaye, Ajit P"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330356","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ajt.15944","locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Case Report"],"weight":1,"_version_":1666138494612799488,"score":249.26508},{"pmid":32476261,"title":"Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2.","text":["Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2.","There is emerging data depicting the clinical presentation of COVID-19 in solid organ transplant recipients but negligible data-driven guidance on clinical management. A biphasic course has been described in some infected with SARS-CoV-2, beginning with a flu-like illness followed by an intense inflammatory response characterized by elevated c-reactive protein (CRP), interleukin 6 (IL-6), and acute respiratory distress syndrome (ARDS) associated with high mortality. The exuberant and possibly dysregulated immune response has prompted interest in therapeutic agents that target the cytokines involved, particularly IL-6. Tocilizumab is an IL-6 receptor antagonist with a record of use for a variety of rheumatologic conditions and cytokine release syndrome due to CAR T-cell therapy but experience in solid organ and composite tissue transplant recipients (SOT/CTTRs) with SARS-CoV-2-related ARDS has not been previously reported in detail. We present the clinical course of five SOT/CTTRs with SARS-CoV-2-related ARDS that received tocilizumab with favorable short-term outcomes in four. Responses were characterized by reductions in CRP, discontinuation of vasopressors, improved oxygenation and respiratory mechanics, and variable duration of ventilator support. Four bacterial infections occurred within two weeks of tocilizumab administration. We discuss safety concerns and the need for randomized comparative trials to delineate tocilizumab's clinical utility in this population.","Am J Transplant","Morillas, Jose A","Marco Canosa, Francisco","Srinivas, Pavithra","Asadi, Tannaz","Calabrese, Casandra","Rajendram, Prabalini","Budev, Marie","Poggio, Emilio D","Narayanan Menon, K V","Gastman, Brian","Koval, Christine","32476261"],"abstract":["There is emerging data depicting the clinical presentation of COVID-19 in solid organ transplant recipients but negligible data-driven guidance on clinical management. A biphasic course has been described in some infected with SARS-CoV-2, beginning with a flu-like illness followed by an intense inflammatory response characterized by elevated c-reactive protein (CRP), interleukin 6 (IL-6), and acute respiratory distress syndrome (ARDS) associated with high mortality. The exuberant and possibly dysregulated immune response has prompted interest in therapeutic agents that target the cytokines involved, particularly IL-6. Tocilizumab is an IL-6 receptor antagonist with a record of use for a variety of rheumatologic conditions and cytokine release syndrome due to CAR T-cell therapy but experience in solid organ and composite tissue transplant recipients (SOT/CTTRs) with SARS-CoV-2-related ARDS has not been previously reported in detail. We present the clinical course of five SOT/CTTRs with SARS-CoV-2-related ARDS that received tocilizumab with favorable short-term outcomes in four. Responses were characterized by reductions in CRP, discontinuation of vasopressors, improved oxygenation and respiratory mechanics, and variable duration of ventilator support. Four bacterial infections occurred within two weeks of tocilizumab administration. We discuss safety concerns and the need for randomized comparative trials to delineate tocilizumab's clinical utility in this population."],"journal":"Am J Transplant","authors":["Morillas, Jose A","Marco Canosa, Francisco","Srinivas, Pavithra","Asadi, Tannaz","Calabrese, Casandra","Rajendram, Prabalini","Budev, Marie","Poggio, Emilio D","Narayanan Menon, K V","Gastman, Brian","Koval, Christine"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476261","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/ajt.16080","topics":["Treatment"],"weight":1,"_version_":1668437835052482560,"score":247.07854}]}